Skip to Content

BIMERVAX XBB.1.16. COVID-19 Vaccine (recombinant, adjuvanted)

Licence status
Authorised: 12/12/2024
Active substances
SARS-CoV-2, variant XBB.1.16, spike protein, receptor binding domain fusion homodimer
Dosage Form
Emulsion for injection
Licence number
EU/1/22/1709/004-007
Licence holder
Hipra Human Health S.L.

Licence information

ATC code
J07BN04 covid-19, protein subunit
Legal supply status
Product subject to prescription which may not be renewed (A)
Place of sale
Supply through pharmacies only
Conditions of Licence
Medicinal product subject to medical prescription. • Official batch release In accordance with Article 114 of Directive 2001/83/EC, the official batch release will be undertaken by a state laboratory or a laboratory designated for that purpose.
Marketing availability
Unknown
Advertising conditions
Advertising to healthcare professionals only
Licence issued
12/12/2024